Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1995 2
1996 1
1997 2
1998 2
1999 2
2000 9
2001 1
2002 1
2003 1
2004 7
2005 4
2006 5
2008 5
2009 4
2010 6
2011 5
2012 5
2013 1
2014 9
2015 7
2016 9
2017 5
2018 5
2020 5
2021 0
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 33384307

97 results
Results by year
Filters applied: . Clear all
Page 1
Prostate cancer screening and the role of PSA: A UK perspective.
Sooriakumaran P. Sooriakumaran P. Cleve Clin J Med. 2020 Dec 31;88(1):14-16. doi: 10.3949/ccjm.88a.20164. Cleve Clin J Med. 2020. PMID: 33384307 Free article. No abstract available.
Optimization of PSA screening policies: a comparison of the patient and societal perspectives.
Zhang J, Denton BT, Balasubramanian H, Shah ND, Inman BA. Zhang J, et al. Med Decis Making. 2012 Mar-Apr;32(2):337-49. doi: 10.1177/0272989X11416513. Epub 2011 Sep 20. Med Decis Making. 2012. PMID: 21933990 Free PMC article.
Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study.
Young GJ, Harrison S, Turner EL, Walsh EI, Oliver SE, Ben-Shlomo Y, Evans S, Lane JA, Neal DE, Hamdy FC, Donovan JL, Martin RM, Metcalfe C. Young GJ, et al. BMJ Open. 2017 Oct 30;7(10):e017729. doi: 10.1136/bmjopen-2017-017729. BMJ Open. 2017. PMID: 29084797 Free PMC article.
Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.
Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, Hamdy F, Stephens P, Lane JA, Moore R, Donovan J. Collin SM, et al. Lancet Oncol. 2008 May;9(5):445-52. doi: 10.1016/S1470-2045(08)70104-9. Epub 2008 Apr 16. Lancet Oncol. 2008. PMID: 18424233 Free PMC article.
Cost-effectiveness analysis of prostate cancer screening.
Hamashima C, Yoshida K. Hamashima C, et al. Environ Health Prev Med. 2000 Oct;5(3):111-7. doi: 10.1265/ehpm.2000.111. Environ Health Prev Med. 2000. PMID: 21432194 Free PMC article.
Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study.
Leal J, Welton NJ, Martin RM, Donovan J, Hamdy F, Neal D, Noble S, Lane A, Wolstenholme J. Leal J, et al. Cancer Epidemiol. 2018 Feb;52:99-105. doi: 10.1016/j.canep.2017.12.002. Epub 2018 Jan 4. Cancer Epidemiol. 2018. PMID: 29278842
The use of prostate specific antigen for prostate cancer screening: a managed care perspective.
Handley MR, Stuart ME. Handley MR, et al. J Urol. 1994 Nov;152(5 Pt 2):1689-92. doi: 10.1016/s0022-5347(17)32362-5. J Urol. 1994. PMID: 7523716 Review.
Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
Gulati R, Gore JL, Etzioni R. Gulati R, et al. Ann Intern Med. 2013 Feb 5;158(3):145-53. doi: 10.7326/0003-4819-158-3-201302050-00003. Ann Intern Med. 2013. PMID: 23381039 Free PMC article.
Unravelling the prostate-specific antigen controversy: a West of Scotland perspective.
Zafar N, Miller S, Leburn V, Qureshi KN, Rajan P. Zafar N, et al. Scott Med J. 2014 May;59(2):126-9. doi: 10.1177/0036933014528618. Epub 2014 Mar 28. Scott Med J. 2014. PMID: 24682103
Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
Brindle LA, Oliver SE, Dedman D, Donovan JL, Neal DE, Hamdy FC, Lane JA, Peters TJ. Brindle LA, et al. BJU Int. 2006 Oct;98(4):777-82. doi: 10.1111/j.1464-410X.2006.06401.x. BJU Int. 2006. PMID: 16978272 Free article.
97 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback